MiR-608 overexpression in idiopathic pulmonary fibrosis (IPF).
CdC42
ILD
IPF
SNP
microRNA
Journal
BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563
Informations de publication
Date de publication:
05 Jan 2021
05 Jan 2021
Historique:
received:
21
10
2020
accepted:
09
12
2020
entrez:
6
1
2021
pubmed:
7
1
2021
medline:
7
9
2021
Statut:
epublish
Résumé
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease that causes scarring of the lungs. The disease is associated with the usual interstitial pneumonia pattern, which was not yet fully recapitulated by an animal model. Therefore, the disease is considered 'human specific'. miRNA-608 is a primate specific miRNA with many potential targets, such CdC42 and Interlukin-6 (IL-6) that were previously implicated in IPF pathology. To test miR-608 expression and its targets in IPF patient samples. RNA was extracted from Formalin fixed paraffin embedded tissue sections (N = 18). miRNA-608 and Cdc42 and IL-6 levels were analyzed by qPCR. Acetylcholinesterase (AChE) is another target of miRNA-608. Its' rs17228616 allele has a single-nucleotide polymorphism causing weakened miR-608 interaction (C2098A). Thus, DNA was extracted from whole blood samples from 56 subjects with fibrosing interstitial lung disease and this region was sequenced for assessment of rs17228616 allele polymorphism. miR-608 is significantly overexpressed in IPF samples in comparison with controls (p < 0.05). Cdc42 and IL-6 levels were lower in the IPF patient samples compared with control samples (p < 0.001 and p < 0.05, respectively). The frequency of the rs17228616 minor A-allele was 17/56 (30.4%) with all patients being heterozygous. This result is significant vs. the published Israeli cohort of healthy individuals, which reported 17% prevalence of this allele in healthy control volunteers (p = 0.01, OR = 2.1, CI 95% [1.19-3.9]). miR-608 is overexpressed in IPF patients. While the exact mechanism remains to be discovered, it could potentially promote fibrotic disease.
Sections du résumé
BACKGROUND
BACKGROUND
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease that causes scarring of the lungs. The disease is associated with the usual interstitial pneumonia pattern, which was not yet fully recapitulated by an animal model. Therefore, the disease is considered 'human specific'. miRNA-608 is a primate specific miRNA with many potential targets, such CdC42 and Interlukin-6 (IL-6) that were previously implicated in IPF pathology.
OBJECTIVE
OBJECTIVE
To test miR-608 expression and its targets in IPF patient samples.
METHODS
METHODS
RNA was extracted from Formalin fixed paraffin embedded tissue sections (N = 18). miRNA-608 and Cdc42 and IL-6 levels were analyzed by qPCR. Acetylcholinesterase (AChE) is another target of miRNA-608. Its' rs17228616 allele has a single-nucleotide polymorphism causing weakened miR-608 interaction (C2098A). Thus, DNA was extracted from whole blood samples from 56 subjects with fibrosing interstitial lung disease and this region was sequenced for assessment of rs17228616 allele polymorphism.
RESULTS
RESULTS
miR-608 is significantly overexpressed in IPF samples in comparison with controls (p < 0.05). Cdc42 and IL-6 levels were lower in the IPF patient samples compared with control samples (p < 0.001 and p < 0.05, respectively). The frequency of the rs17228616 minor A-allele was 17/56 (30.4%) with all patients being heterozygous. This result is significant vs. the published Israeli cohort of healthy individuals, which reported 17% prevalence of this allele in healthy control volunteers (p = 0.01, OR = 2.1, CI 95% [1.19-3.9]).
CONCLUSION
CONCLUSIONS
miR-608 is overexpressed in IPF patients. While the exact mechanism remains to be discovered, it could potentially promote fibrotic disease.
Identifiants
pubmed: 33402146
doi: 10.1186/s12890-020-01377-3
pii: 10.1186/s12890-020-01377-3
pmc: PMC7786457
doi:
Substances chimiques
GPI-Linked Proteins
0
IL6 protein, human
0
Interleukin-6
0
MIRN608 microRNA, human
0
MicroRNAs
0
ACHE protein, human
EC 3.1.1.7
Acetylcholinesterase
EC 3.1.1.7
CDC42 protein, human
EC 3.6.5.2
cdc42 GTP-Binding Protein
EC 3.6.5.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1Références
Oldham JM, Collard HR. Comorbid conditions in idiopathic pulmonary fibrosis: recognition and management. Front Med (Lausanne). 2017;4:123.
doi: 10.3389/fmed.2017.00123
Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824.
doi: 10.1164/rccm.2009-040GL
Tashiro J, Rubio GA, Limper AH, Williams K, Elliot SJ, Ninou I, et al. Exploring animal models that resemble idiopathic pulmonary fibrosis. Front Med (Lausanne). 2017;4:118.
doi: 10.3389/fmed.2017.00118
O’Brien J, Hayder H, Zayed Y, Peng C. Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol (Lausanne). 2018;9:402.
doi: 10.3389/fendo.2018.00402
Macfarlane LA, Murphy PR. MicroRNA: biogenesis, function and role in cancer. Curr Genom. 2010;11(7):537–61.
doi: 10.2174/138920210793175895
Noth I, Zhang Y, Ma SF, Flores C, Barber M, Huang Y, et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir Med. 2013;1(4):309–17.
doi: 10.1016/S2213-2600(13)70045-6
Manichaikul A, Wang XQ, Sun L, Dupuis J, Borczuk AC, Nguyen JN, et al. Genome-wide association study of subclinical interstitial lung disease in MESA. Respir Res. 2017;18(1):97.
doi: 10.1186/s12931-017-0581-2
Ahn MH, Park BL, Lee SH, Park SW, Park JS, Kim DJ, et al. A promoter SNP rs4073T>A in the common allele of the interleukin 8 gene is associated with the development of idiopathic pulmonary fibrosis via the IL-8 protein enhancing mode. Respir Res. 2011;12:73.
doi: 10.1186/1465-9921-12-73
Duan R, Pak C, Jin P. Single nucleotide polymorphism associated with mature miR-125a alters the processing of pri-miRNA. Hum Mol Genet. 2007;16(9):1124–31.
doi: 10.1093/hmg/ddm062
Wang YF, Ao X, Liu Y, Ding D, Jiao WJ, Yu Z, et al. MicroRNA-608 promotes apoptosis in non-small cell lung cancer cells treated with doxorubicin through the inhibition of TFAP4. Front Genet. 2019;10:809.
doi: 10.3389/fgene.2019.00809
Hanin G, Shenhar-Tsarfaty S, Yayon N, Yau YH, Bennett ER, Sklan EH, et al. Competing targets of microRNA-608 affect anxiety and hypertension. Hum Mol Genet. 2014;23(17):4569–80.
doi: 10.1093/hmg/ddu170
Kang JG, Majerciak V, Uldrick TS, Wang X, Kruhlak M, Yarchoan R, et al. Kaposi’s sarcoma-associated herpesviral IL-6 and human IL-6 open reading frames contain miRNA binding sites and are subject to cellular miRNA regulation. J Pathol. 2011;225(3):378–89.
doi: 10.1002/path.2962
Wu H, Yu Y, Huang H, Hu Y, Fu S, Wang Z, et al. Progressive pulmonary fibrosis is caused by elevated mechanical tension on alveolar stem cells. Cell. 2020;180(1):107-121e117.
doi: 10.1016/j.cell.2019.11.027
Epstein Shochet G, Brook E, Bardenstein-Wald B, Shitrit D. TGF-beta pathway activation by idiopathic pulmonary fibrosis (IPF) fibroblast derived soluble factors is mediated by IL-6 trans-signaling. Respir Res. 2020;21(1):56.
doi: 10.1186/s12931-020-1319-0
McCormack FX, King TE Jr, Bucher BL, Nielsen L, Mason RJ. Surfactant protein A predicts survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1995;152(2):751–9.
doi: 10.1164/ajrccm.152.2.7633738
Selman M, Carrillo G, Estrada A, Mejia M, Becerril C, Cisneros J, et al. Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PLoS ONE. 2007;2(5):e482.
doi: 10.1371/journal.pone.0000482
Trujillo G, Meneghin A, Flaherty KR, Sholl LM, Myers JL, Kazerooni EA, et al. TLR9 differentiates rapidly from slowly progressing forms of idiopathic pulmonary fibrosis. Sci Transl Med. 2010;2(57):57ra82.
doi: 10.1126/scitranslmed.3001510
Balestro E, Calabrese F, Turato G, Lunardi F, Bazzan E, Marulli G, et al. Immune inflammation and disease progression in idiopathic pulmonary fibrosis. PLoS ONE. 2016;11(5):e0154516.
doi: 10.1371/journal.pone.0154516
Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. N Engl J Med. 2018;379(8):797–8.
pubmed: 30134133
McDonough JE, Ahangari F, Li Q, Jain S, Verleden SE, Herazo-Maya J, et al. Transcriptional regulatory model of fibrosis progression in the human lung. JCI Insight. 2019;4(22):e131597. https://doi.org/10.1172/jci.insight.131597 .
doi: 10.1172/jci.insight.131597
pmcid: 6948862
Bagnato G, Roberts WN, Roman J, Gangemi S. A systematic review of overlapping microRNA patterns in systemic sclerosis and idiopathic pulmonary fibrosis. Eur Respir Rev. 2017;26(144):160125. https://doi.org/10.1183/16000617.0125-2016 .
doi: 10.1183/16000617.0125-2016
pubmed: 28515040
Wang Z, Xue Y, Wang P, Zhu J, Ma J. MiR-608 inhibits the migration and invasion of glioma stem cells by targeting macrophage migration inhibitory factor. Oncol Rep. 2016;35(5):2733–42.
doi: 10.3892/or.2016.4652
Liang Z, Wang X, Xu X, Xie B, Ji A, Meng S, et al. MicroRNA-608 inhibits proliferation of bladder cancer via AKT/FOXO3a signaling pathway. Mol Cancer. 2017;16(1):96.
doi: 10.1186/s12943-017-0664-1
Miao Z, Guo X, Tian L. The long noncoding RNA NORAD promotes the growth of gastric cancer cells by sponging miR-608. Gene. 2019;687:116–24.
doi: 10.1016/j.gene.2018.11.052
Zhang Y, Schiff D, Park D, Abounader R. MicroRNA-608 and microRNA-34a regulate chordoma malignancy by targeting EGFR, Bcl-xL and MET. PLoS ONE. 2014;9(3):e91546.
doi: 10.1371/journal.pone.0091546
Yang PW, Huang YC, Hsieh CY, Hua KT, Huang YT, Chiang TH, et al. Association of miRNA-related genetic polymorphisms and prognosis in patients with esophageal squamous cell carcinoma. Ann Surg Oncol. 2014;21(Suppl 4):S601-609.
doi: 10.1245/s10434-014-3709-3
Yu HX, Wang XM, Han XD, Cao BF. MiR-608 exerts tumor suppressive function in lung adenocarcinoma by directly targeting MIF. Eur Rev Med Pharmacol Sci. 2018;22(15):4908–16.
pubmed: 30070326
Dai ZM, Kang HF, Zhang WG, Li HB, Zhang SQ, Ma XB, et al. The associations of single nucleotide polymorphisms in miR196a2, miR-499, and miR-608 with breast cancer susceptibility: a STROBE-compliant observational study. Medicine (Baltimore). 2016;95(7):e2826.
doi: 10.1097/MD.0000000000002826
Pardini B, Rosa F, Naccarati A, Vymetalkova V, Ye Y, Wu X, et al. Polymorphisms in microRNA genes as predictors of clinical outcomes in colorectal cancer patients. Carcinogenesis. 2015;36(1):82–6.
doi: 10.1093/carcin/bgu224
Li MP, Hu YD, Hu XL, Zhang YJ, Yang YL, Jiang C, et al. MiRNAs and miRNA polymorphisms modify drug response. Int J Environ Res Public Health. 2016;13(11):1096.
doi: 10.3390/ijerph13111096
Gershman E, Zer A, Pertzov B, Shtraichman O, Shitenberg D, Heching M, et al. Characteristics of lung cancer in idiopathic pulmonary fibrosis with single lung transplant versus non-transplanted patients: a retrospective observational study. BMJ Open Respir Res. 2020;7(1):e000566.
doi: 10.1136/bmjresp-2020-000566
Gu W, Wen D, Lu H, Zhang A, Wang H, Du J, et al. MiR-608 exerts anti-inflammatory effects by targeting ELANE in monocytes. J Clin Immunol. 2019;40:147–57.
doi: 10.1007/s10875-019-00702-8
Le TT, Karmouty-Quintana H, Melicoff E, Le TT, Weng T, Chen NY, et al. Blockade of IL-6 Trans signaling attenuates pulmonary fibrosis. J Immunol. 2014;193(7):3755–68.
doi: 10.4049/jimmunol.1302470
Lee YJ, Choi SM, Lee YJ, Cho YJ, Yoon HI, Lee JH, et al. Clinical impact of depression and anxiety in patients with idiopathic pulmonary fibrosis. PLoS ONE. 2017;12(9):e0184300.
doi: 10.1371/journal.pone.0184300
Akhtar AA, Ali MA, Smith RP. Depression in patients with idiopathic pulmonary fibrosis. Chron Respir Dis. 2013;10(3):127–33.
doi: 10.1177/1479972313493098
Ryerson CJ, Berkeley J, Carrieri-Kohlman VL, Pantilat SZ, Landefeld CS, Collard HR. Depression and functional status are strongly associated with dyspnea in interstitial lung disease. Chest. 2011;139(3):609–16.
doi: 10.1378/chest.10-0608
Lindell KO, Olshansky E, Song MK, Zullo TG, Gibson KF, Kaminski N, et al. Impact of a disease-management program on symptom burden and health-related quality of life in patients with idiopathic pulmonary fibrosis and their care partners. Heart Lung. 2010;39(4):304–13.
doi: 10.1016/j.hrtlng.2009.08.005
Holland AE, Fiore JF Jr, Bell EC, Goh N, Westall G, Symons K, et al. Dyspnoea and comorbidity contribute to anxiety and depression in interstitial lung disease. Respirology. 2014;19(8):1215–21.
doi: 10.1111/resp.12360
Walters K, Rait G, Griffin M, Buszewicz M, Nazareth I. Recent trends in the incidence of anxiety diagnoses and symptoms in primary care. PLoS ONE. 2012;7(8):e41670.
doi: 10.1371/journal.pone.0041670